Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis

Stangel, Martin; Boegner, Friedrich; Klatt, Christel H.; Hofmeister, Christoph; Seyfert, Sepp
January 2000
Journal of Neurology, Neurosurgery & Psychiatry;Jan2000, p89
Academic Journal
No abstract available.


Related Articles

  • Combinations of drugs.  // Multiple Sclerosis (13524585);Sep99 Supplement, Vol. 5, pS95 

    The article presents abstracts of medical research related to multiple sclerosis. They include "Continuous Combined Immunomodulatory-Immunosuppressive (IMIS) Therapy in Multiple Sclerosis," "Combination Therapy of Interferon β With Immunosuppressive Drugs in Multiple Sclerosis: A Pilot...

  • Immunoglobulin benefits patients with multiple sclerosis.  // BMJ: British Medical Journal (International Edition);03/08/98, Vol. 314 Issue 7082, p696 

    Focuses on results of a placebo controlled trial of 150 people with relapsing remitting multiple sclerosis that monthly intravenous immunoglobulin was effective and well-tolerated.

  • Promotion of Remyelination by Immunoglobulins: Implications for the Treatment of Multiple Sclerosis. Trebst, C.; Stangel, M. // Current Pharmaceutical Design;Jan2006, Vol. 12 Issue 2, p241 

    During the last decade immunomodulatory treatments have been shown to influence the natural course of multiple sclerosis (MS). However, demyelination in the central nervous system (CNS) still occurs and repair mechanisms are incomplete leading to neurological deficits. Currently, there is no...

  • Use of immune globulin therapy for multiple sclerosis. Walling, Anne D. // American Family Physician;11/1/1997, Vol. 56 Issue 7, p1880 

    Presents a summary of the article `Randomised Placebo-Controlled Trial of Monthly Intravenous Immune Globulin Therapy in Relapsing-Remitting Multiple Sclerosis,' by F. Fazekas from the journal `Lancet' dated 1997. Management for multiple sclerosis; Result of the study on patients receiving...

  • Use of Intravenous Immunoglobulin in Multiple Sclerosis. Achiron, A.; Barak, Y.; Sarova-Pinhas, I. // BioDrugs;1998, Vol. 9 Issue 6, p465 

    Intravenous immunoglobulin (IVIg) pooled from healthy human volunteers has a role in several immunomodulating mechanisms which may affect the pathogenesis of multiple sclerosis. Modulation of the disease course by IVIg is achieved both by limiting the inflammatory process and by enhancing...

  • Understanding tissue destruction II.  // Multiple Sclerosis (13524585);Sep99 Supplement, Vol. 5, pS3 

    The article presents abstracts of medical research related to multiple sclerosis. They include "Oligodendrocyte Susceptibility to Immune Mediated Injury and Related Oral Presentations," "Remyelinated Central Axons are Vulnerable to Damage Caused by Electrical Impulse Activity," and...

  • IVIG trials in MS. Is albumin a placebo? Hommes, Otto; Haas, Judith; Soelberg-Sorenson, Per; Friedrichs, Mieke // Journal of Neurology;Feb2009, Vol. 256 Issue 2, p268 

    A letter to the editor is presented on the effects of intravenous immunoglobulin treatments for multiple sclerosis patients.

  • Clinical trials in MS -- Developments and challenges.  // Multiple Sclerosis (13524585);Nov2007, Vol. 13 Issue 9, pS17 

    The article presents abstracts on medical topics which include the examination of the ethics of placebo-controlled clinical trials in multiple sclerosis, the study of the statistical challenges in combination trials in multiple sclerosis, and the study of the clinical effects of the...

  • Immunotherapy of multiple sclerosis--Current practice and future directions. Tullman, Mark J.; Lublin, Fred D.; Miller, Aaron E. // Journal of Rehabilitation Research & Development;Mar/Apr2002, Vol. 39 Issue 2, p273 

    Reviews several therapies that have been studied to treat multiple sclerosis. Treatment of acute attacks; Details on disease-modifying agents; Information on intravenous immunoglobulin.

  • Overview of European pilot study of interferon �-1b in primary progressive multiple sclerosis. Montalban, Xavier // Multiple Sclerosis (13524585);Jun2004 Supplement, Vol. 10 Issue 1S, pS62 

    This short monograph describes a trial of interferon �- 1b in patients with primary progressive multiple sclerosis (PPMS) or transitional MS. Designed as a randomized, placebo-controlled pilot, the trial randomly placed 73 eligible patients into two groups, placebo or interferon �-1b 8...


Read the Article


Sign out of this library

Other Topics